Logo-apb

Journal Info:

Freq.: Quarterly

eISSN: 2251-7308 
pISSN: 2228-5881 

Permission: CC By

Platinum Open Access

(no submission or publication fees)

Powered by
Adv Pharm Bull. 2015;5(4): 463-469. doi: 10.15171/apb.2015.063
PMID: 26819917        PMCID: PMC4729352

Original Research

Short-Term Treatment with Silymarin Improved 6-OHDA-Induced Catalepsy and Motor Imbalance in Hemi-Parkisonian Rats

Rasool Haddadi 1, Shahla Eyvari Brooshghalan 2, Safar Farajniya 2, Alireza Mohajjel Nayebi 2,3 * , Hamdolah Sharifi 4

Cited by CrossRef: 14

1- Grembecka B, Majkutewicz I, Harackiewicz O, Wrona D. Deep-Brain Subthalamic Nucleus Stimulation Enhances Food-Related Motivation by Influencing Neuroinflammation and Anxiety Levels in a Rat Model of Early-Stage Parkinson’s Disease. IJMS. 2023;24(23):16916 [Crossref]
2- Almutary A, Begum M, Siddiqua A, Gupta S, Chauhan P, Wadhwa K, Singh G, Iqbal D, Padmapriya G, Kumar S, Kedia N, Verma R, Kumar R, Sinha A, Dheepak B, Abomughaid M, Jha N. Unlocking the Neuroprotective Potential of Silymarin: A Promising Ally in Safeguarding the Brain from Alzheimer’s Disease and Other Neurological Disorders. Mol Neurobiol. 2025; [Crossref]
3- Haddadi R, Poursina M, Zeraati F, Nadi F. Gastrodin microinjection suppresses 6-OHDA-induced motor impairments in parkinsonian rats: insights into oxidative balance and microglial activation in SNc. Inflammopharmacol. 2018;26(5):1305 [Crossref]
4- Haddadi R, Nayebi A, Eyvari Brooshghalan S. RETRACTED: Silymarin prevents apoptosis through inhibiting the Bax/caspase-3 expression and suppresses toll like receptor-4 pathway in the SNc of 6-OHDA intoxicated rats. Biomedicine & Pharmacotherapy. 2018;104:127 [Crossref]
5- Eyvari Brooshghalan S, Sabahi M, Ebadi S, Sadeghian Z, Mohajjel Nayebi A, Haddadi R. Silibinin chronic treatment in a rat model of Parkinson disease: A comprehensive in-vivo evaluation and in silico molecular modeling. European Journal of Pharmacology. 2023;941:175517 [Crossref]
6- Prajapati S, Garabadu D, Krishnamurthy S. Coenzyme Q10 Prevents Mitochondrial Dysfunction and Facilitates Pharmacological Activity of Atorvastatin in 6-OHDA Induced Dopaminergic Toxicity in Rats. Neurotox Res. 2017;31(4):478 [Crossref]
7- Haddadi R, Eyvari-Brooshghalan S, Makhdoomi S, Fadaiie A, Komaki A, Daneshvar A. Neuroprotective effects of silymarin in 3-nitropropionic acid-induced neurotoxicity in male mice: improving behavioral deficits by attenuating oxidative stress and neuroinflammation. Naunyn-Schmiedeberg's Arch Pharmacol. 2024;397(4):2447 [Crossref]
8- Prasad E, Hung S. Behavioral Tests in Neurotoxin-Induced Animal Models of Parkinson’s Disease. Antioxidants. 2020;9(10):1007 [Crossref]
9- El-Sayed R, Abdelaziz A, Zaki H, Abdel Rasheed N. Cilostazol novel neuroprotective mechanism against rotenone-induced Parkinson's disease in rats: Correlation between Nrf2 and HMGB1/TLR4/PI3K/Akt/mTOR signaling. International Immunopharmacology. 2023;117:109986 [Crossref]
10- Haddadi R, Shahidi Z, Eyvari-Brooshghalan S. Silymarin and neurodegenerative diseases: Therapeutic potential and basic molecular mechanisms. Phytomedicine. 2020;79:153320 [Crossref]
11- Kheradmand A, Nayebi A, Jorjani M, Khalifeh S, Haddadi R. Effects of WR1065 on 6-hydroxydopamine-induced motor imbalance: Possible involvement of oxidative stress and inflammatory cytokines. Neuroscience Letters. 2016;627:7 [Crossref]
12- Bakhshi F, Molavi O, Rashidi M, Shayanfar A, Amini H. Developing a high-performance liquid chromatography fast and accurate method for quantification of silibinin. BMC Res Notes. 2019;12(1) [Crossref]
13- Ranjan S, Gautam A. Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight. Front Neurosci. 2023;17 [Crossref]
14- Ameen A, Elkazaz A, Mohammad H, Barakat B. Anti-inflammatory and neuroprotective activity of boswellic acids in rotenone parkinsonian rats. Can J Physiol Pharmacol. 2017;95(7):819 [Crossref]